| 1 |
2023 |
Yang Xing, Feroza Yasinjan, Yajie Du, Huayue Geng, Ying Zhang, Minghua He, Rui Guo, Lei Yang, Jiayue Cui, Dongmei Mu, Ziling Liu, Hong Wang. Immunotherapy in cervical cancer: From the view of scientometric analysis and clinical trials, Frontiers in Immunology. 2023; 14: 1094437.
https://doi.org/10.3389/fimmu.2023.1094437 |
| 2 |
2024 |
Shamsnur Rehim, Shuang Yuan, Hongjing Wang, Cho-Hao Howard Lee. Mirvetuximab Soravtansine in solid tumors: A systematic review and meta-analysis, PLOS ONE. 2024; 19: e0310736.
https://doi.org/10.1371/journal.pone.0310736 |
| 3 |
2024 |
Rayna F. Marshall, Hannah Xu, Meghan Berkenstock. Ocular toxicities associated with antibody drug conjugates, Current Opinion in Ophthalmology. 2024; 35: 494.
https://doi.org/10.1097/ICU.0000000000001063 |
| 4 |
2024 |
Chukwunonso K. Nwabufo, Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations, Cancer Chemotherapy and Pharmacology. 2024; 93: 89.
https://doi.org/10.1007/s00280-023-04575-y |
| 5 |
2023 |
Rebecca L. Porter, Ursula A. Matulonis. Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer, Expert Review of Anticancer Therapy. 2023; 23: 783.
https://doi.org/10.1080/14737140.2023.2236793 |
